Trials / Recruiting
RecruitingNCT06055621
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Evaluation of DASATINIB Monotherapy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Institut Paoli-Calmettes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to learn about the efficacy of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE. The main question it aims to answer is to assess the tumor response after 2 cycles of DASATINIB monotherapy treatment for patients with chemotherapy-ineligible acute myeloid leukemia refractory to VENETOCLAX-AZACITIDINE therapy. Participants will be given DASATINIB treatment up to 3 months. Response will be assessed by a myelogram and a complete blood count at the end of every cycle. Follow up will last 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib | Daily orally administration of DASATINIB |
Timeline
- Start date
- 2024-05-22
- Primary completion
- 2026-07-08
- Completion
- 2027-10-31
- First posted
- 2023-09-28
- Last updated
- 2026-03-13
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06055621. Inclusion in this directory is not an endorsement.